Crosstex acquires Accutron

Conscious sedation is safe and effective, induces a relaxed state, decreases anxiety and physical movement, and may eliminate the need for local anesthesia in certain instances. This allows the practitioner to deliver better patient care. All Accutron products are FDA compliant, carry the CE Mark, are registered with Health Canada and manufactured in Accutron’s ISO 13485 facility in Phoenix, Ariz.

“Conscious sedation and the safety and comfort of the patient have always been the focus of our company. From the very beginning we strived to be the market leader and market innovator in conscious sedation technology” said Accutron vice president of sales & marketing Jonathan Blasdell. “We firmly believe that by coming together as one and combining the strengths of the Crosstex marketing network, Accutron’s technology and manufacturing capabilities, and the continued utilization and professionalism of the PSA sales team, we can increase the understanding and expand the use of conscious sedation in dentistry.”

Andrew Whitehead, senior vice president of business development, said, “Crosstex continues to diversify and expand its product portfolio and the markets it serves — all directly related to improving and enhancing the patient experience as it relates to infection prevention, patient safety and comfort. In the past 18 months we have acquired and become the market leader in dental unit waterlines with the acquisitions of DentaPure and Liquid Ultra, entered the industrial market with the acquisition of the NAMSA sterility assurance products division, and have now entered the small-equipment/conscious sedation market with the acquisition of Accutron.”

“With the strong support of our global distribution partners and our marketing/educational focus, we will elevate the awareness of conscious sedation as it relates to increased production for the dental practitioner as well as improving the patient experience in terms of infection prevention, safety and comfort,” said Gary Steinberg, president and CEO, Crosstex. “The addition of Accutron and their employees compliments our strategic vision. Their presence also strengthens our relationship within the dental community, both domestically and internationally, bringing increased awareness to our existing portfolio of infection prevention, safety and compliance products.”

Crosstex manufactures a wide array of infection prevention and compliance products for the global health care industry. Founded in 1953 and headquartered in Hauppauge, N.Y., Crosstex is a recognized leader in products used for waterline treatment, biological monitoring, sterility assurance packaging and personal protection equipment. Sold in more than 100 countries, the products distributed to medical, dental and veterinary practices and facilities include the award-winning (five consecutive years) Secure Fit technology face masks, DentaPure waterline treatment cartridges and Liquid Ultra, Sure-Check sterilization pouches with internal/external multiparameter indicators, Tyvek pouches with 510K approval, SteamPlus Type 5 chemical integrators, ConFirm and Passport Plus in-office and mail-in biological indicators and Rapicide OPA/28 high level disinfectant.

For more on the full line of Crosstex infection-prevention, patient-safety and compliance products, contact Crosstex at (631) 582-6777 or visit www.crosstex.com.

Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other health care providers to improve outcomes, enhance safety and help save lives.

Cantel products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens.

For more information, visit the Cantel website at www.cantelmedical.com.

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel’s filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

(Source: Crosstex)